Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS (dal-GenE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02525939
Recruitment Status : Active, not recruiting
First Posted : August 18, 2015
Last Update Posted : February 3, 2021
The Montreal Health Innovations Coordinating Center (MHICC)
Medpace, Inc.
Roche Molecular Systems, Inc
Information provided by (Responsible Party):
DalCor Pharmaceuticals